BioSight
Companies
Akebia Therapeutics, Inc. logo

AKBA

NASDAQCAMBRIDGE, MA
Akebia Therapeutics, Inc.

Akebia Therapeutics develops pharmaceutical products for kidney disease and related conditions. The company markets Auryxia (ferric citrate) and Vafseo (vadadustat), with plans to expand Vafseo's label and commercialize it further. Akebia acquired Keryx Biopharmaceuticals in 2018 and is focused on selling these products through contracts with dialysis organizations.

Price history not yet available for AKBA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar